Investigational / not FDA-approved

Vesugen

KED tripeptide (Lys-Glu-Asp) — ≠ Pinealon ≠ Prostamax ≠ Epitalon.

Editorial review:

What evidence says

Evidence snapshot

This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.

Identity lock. Vesugen is the synthetic tripeptide Lys-Glu-Asp (KED). PubChem CID 87571363; formula C15H26N4O8 / MW 390.39; CAS commonly cited 204271-66-9. It is a Khavinson-line vascular / neurogenesis short peptide. Vesugen ≠ Pinealon (EDR); ≠ Prostamax (KEDP); ≠ Epitalon (AEDG); ≠ Semax / Selank. This drawer marks papers. It is not use advice.

Bottom line

Literature is preclinical / program-series short-peptide work: KED neurogenesis / Alzheimer’s framing, endothelial aging epigenetics, anti-atherosclerotic molecular narratives, fibroblast aging, stem-cell neuronal differentiation, and polymorbidity aging series that co-list multiple peptides. No modern multi-region Phase 3 vascular drug package is assumed. Refuse anti-aging glow.

Papers

PMID 34173097 — Khavinson 2021

Tested: molecular-genetic aspects of peptide KED regulation of neurogenesis in Alzheimer’s disease framing.

Does not show: a completed human AD Phase 3.

PMID 18546825 — Kozina 2008

Tested: antihypoxic properties of short peptides (Vesugen-class short peptides among series).

Does not show: Vesugen monotherapy human hypoxia RCT.

PMID 18546826 — Kozina 2008

Tested: biological activity of regulatory peptides in in vitro model experiments (series including vascular peptides).

Does not show: clinical outcomes.

PMID 25051766 — Khavinson 2014

Tested: epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging.

Does not show: human cardiovascular outcome trial.

PMID 25408528 — Khavinson 2014

Tested: molecular aspects of anti-atherosclerotic effects of short peptides.

Does not show: approved atherosclerosis indication.

PMID 26390612 — Meshchaninov 2015

Tested: synthetic peptides in aging patients with chronic polymorbidity and organic brain syndrome (multi-peptide program series).

Does not show: Vesugen-only confirmatory CONSORT RCT.

PMID 27259496 — Linkova 2016

Tested: peptide regulation of skin fibroblast functions during aging in vitro.

Does not show: human dermatologic drug approval.

PMID 30791821 — Caputi 2019

Tested: short peptides on neuronal differentiation of stem cells (includes KED-class short peptides).

Does not show: human regenerative indication.

PMID 39518916 — Kraskovskaya 2024

Tested: short peptides protecting fibroblast-derived induced neurons from age-related changes.

Does not show: human clinical neuroprotection proof.

What is not established

Modern pivotal human efficacy for Vesugen. Interchangeability with Pinealon, Prostamax, or Epitalon. Anti-aging or vascular-wellness claims. This drawer does not provide use advice, schedules, or sourcing.

Selected sources

34173097 18546825 18546826 25051766 25408528 26390612 27259496 30791821 39518916

What people discuss

Reported experiences

Reported topics are not established benefits.

Watch for

Risks and unknowns

Context matters. Approval of one medicine, formulation, or use does not establish approval of products sold online or other uses. This page is educational and does not provide dosing or treatment advice.

Member discussion

Compare experiences with care.

Before posting: Describe firsthand observations and uncertainty. Do not prescribe, arrange transactions, or post private health information.

◎Verified members

Join the discussion

Verified members can contribute to compound conversations.

No approved member reports yet. Thoughtful first contributions are welcome.